Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.

Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine. 2019 Nov 14;: Authors: Newall AT, Wood JG, Chen C, McIntyre P, Beutels P PMID: 31733945 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31733945?dopt=Abstract

Source: Vaccine - November 13, 2019 Category: Allergy & Immunology Authors: Newall AT, Wood JG, Chen C, McIntyre P, Beutels P Tags: Vaccine Source Type: research

More News: Allergy & Immunology | Australia Health | Meningitis Vaccine | Pneomococcal Vaccine | Vaccines